Haemodialysis (HD) treatment affects around 0.1% of the population but requires 5 to 10% of overall health costs in developed countries due to complex and chronic patient care. Since quality and process control of HD treatment is nowadays not based on an assessment of patient-specific biochemical and procedural dialysis measures, the ProDial project aims at developing an individual approach based on the granular characterization of the patients’ surrogate biodata of sympathetic activation following HD treatment, physical activity, sleep quality, recovery time, self-reported tolerability outcome and HD machine data with the goal to increase individual treatment outcome and tolerability. Innovative and anonymized data gathering and validation procedures will assure integrated and structured data storages while innovative mechanisms will analyze the contained data to enable personalized HD treatment procedures with intelligent comorbidity and tolerability adaptation in the future.